Atavistik Bio Presents Innovative Findings at ASH 2025
Atavistik Bio is set to reveal groundbreaking results concerning its development of novel allosteric JAK2 V617F selective inhibitors. These inhibitors aim at effectively treating myeloproliferative neoplasms (MPNs) while sparing normal JAK2 activity, thereby reducing complications. This major announcement will take place at the upcoming ASH Annual Meeting and Exhibition.
The Challenge of Myeloproliferative Neoplasms
Myeloproliferative neoplasms are a group of blood cancers that arise due to the uncontrolled growth of blood cells in the bone marrow. Among these, the JAK2 V617F mutation represents a critical target for therapeutic interventions. Approximately 95% of patients with polycythemia vera, around 60% with essential thrombocythemia, and 55% with myelofibrosis carry this mutation. These statistics highlight the pressing need for effective treatments that specifically address this mutation.
Introducing Allosteric Inhibitors
The innovative inhibitors being developed by Atavistik Bio are designed to specifically target the mutant JAK2 V617F and inhibit its activity without affecting the wild-type JAK2. This selective approach promises to minimize the adverse effects commonly associated with pan-JAK inhibitors, which can indiscriminately inhibit both mutant and normal JAK2 activity, leading to various complications.
Preclinical Data Highlights
Preclinical studies have shown that Atavistik's JAK2 V617F mutant-selective inhibitors exhibit remarkable potency, demonstrating picomolar affinity towards the JAK2 V617F mutant. This drug candidate was created through a sophisticated structure-based drug design process, showcasing over 100-fold selectivity against other kinases in the JAK family.
Mechanism of Action
The unique mechanism of these inhibitors allows them to bind specifically to the allosteric pseudokinase JH2 domain of JAK2. In cellular models, they have shown powerful inhibition of signaling pathways dependent on the JAK2 V617F mutation while sparing cells expressing normal JAK2. This precision is crucial for improving patient outcomes in terms of both efficacy and safety.
Clinical Development and Future Directions
Atavistik Bio is advancing these compounds into further development based on their favorable pharmacokinetic properties and tolerability. The promising results observed in early trials pave the way for exploring these inhibitors in clinical settings, focusing on creating effective treatment protocols for patients suffering from MPNs.
Insights from Atavistik Bio Leadership
“We are excited to showcase our findings at the ASH meeting,” stated Marion Dorsch, Ph.D., President and Chief Scientific Officer at Atavistik Bio. “Our highly selective allosteric inhibitors represent a significant advancement over existing treatments, aiming to provide long-term benefits while reducing the risk of hematological side effects.”
Details of the ASH Presentation
At the ASH Annual Meeting, Atavistik Bio will deliver a presentation titled “Discovery of JAK2 V617F Mutant-Specific Allosteric Inhibitors for the Treatment of Myeloproliferative Neoplasms”. This will be featured during Session 631, focused on Myeloproliferative Syndromes and Chronic Myeloid Leukemia. The presentation is scheduled for December 6, 2025.
About Atavistik Bio
Atavistik Bio is a clinical-stage biotechnology firm concentrating on the discovery and development of transformative therapeutics targeting severe unmet patient needs. Their innovative approach leverages allostery to create a pipeline of promising therapeutic candidates. Currently, Atavistik is advancing various products, including ATV-1601, an allosteric selective inhibitor designed for solid tumors.
Contact Information
For media inquiries, please contact:
Liz Melone
Melone Communications, LLC
Email: liz@melonecomm.com
Frequently Asked Questions
1. What are JAK2 V617F selective inhibitors?
They are therapeutic agents specifically targeting the JAK2 V617F mutation, aiming to treat related blood cancers while minimizing side effects.
2. How do these inhibitors differ from pan-JAK inhibitors?
Unlike pan-JAK inhibitors, which affect both mutant and normal JAK2, these selective inhibitors focus solely on the mutant, reducing adverse effects.
3. What is myeloproliferative neoplasm?
It’s a type of blood cancer involving the overproduction of blood cells due to mutations in blood stem cells.
4. When will the findings be presented?
The findings will be shared at the ASH Annual Meeting on December 6, 2025.
5. What is the mission of Atavistik Bio?
Atavistik Bio aims to develop innovative allosteric therapeutics to address serious health conditions and improve patient outcomes.
